Study on the Effectiveness and Safety of Shuxinin Injection in the Treatment of Acute Ischemic Stroke
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-parallel-controlled multiplier designed to
observe and evaluate the efficacy and safety of Shuxuening injection in the treatment of
acute ischemic stroke for 10 days and continue follow-up to 90 days after the onset of the
disease.